Obesity Pharmacotherapy: Comparative Efficacy and Safety in Adults
Key Takeaways
- All included medications were associated with greater weight loss than placebo, with semaglutide and tirzepatide showing the largest reductions.
- Discontinuation rates were similar to placebo overall, while serious adverse events were generally not increased except with naltrexone plus bupropion.
- Cardiovascular, metabolic, durability, and subgroup findings varied by medication, and the primary weight-loss evidence was rated high certainty despite limited long-term and comparative data.
A Nature Medicine network meta-analysis evaluated six obesity management medications across 56 randomized trials involving 60,307 adults. The primary outcome was percentage of total body weight loss at the study endpoint. Each agent was associated with greater total body weight loss than placebo at study end. Semaglutide and tirzepatide were the only medications surpassing 10% total body weight loss in the pooled endpoint analysis. Overall, the results reflected medication-level effects rather than a uniform pattern across the treatment group.
Timepoint analyses showed the same general ordering, with semaglutide and tirzepatide producing the largest body-weight reductions among the included medications. At 52 weeks, orlistat was the only agent without a significant advantage over placebo. When later follow-up data were available, estimated effects were broadly similar to the endpoint pattern. Direct drug-to-drug comparisons were limited, so most relative estimates came from indirect network comparisons. The comparative pattern remained medication-specific, with performance varying across individual agents over follow-up.
Investigators found no significant overall between-group difference in treatment discontinuation across the reviewed trials. Serious adverse events were generally not increased, although naltrexone plus bupropion was an exception. For cardiometabolic outcomes, tirzepatide showed the largest HbA1c reduction, while liraglutide and semaglutide had larger fasting plasma glucose declines. Naltrexone plus bupropion increased systolic blood pressure, whereas several other medications improved blood pressure and lipid measures. In aggregate, these non-weight findings differentiated agents by safety and metabolic profile.
Pooled cardiovascular results also varied by medication. These analyses drew on externally adjudicated endpoints for major adverse cardiovascular events (MACE), cardiovascular mortality, and hospitalization for heart failure (HHF) as reported across the included trials. Semaglutide was the only agent associated with a significantly lower rate of major adverse cardiovascular events overall. Tirzepatide was linked to fewer heart-failure hospitalizations, while semaglutide and naltrexone plus bupropion were associated with lower cardiovascular mortality. These associations suggested cardiovascular signals were not shared evenly across the medication group.
Post-discontinuation analyses showed weight regain of 47% after liraglutide discontinuation, 43% after 26 weeks off semaglutide, 67% after 52 weeks off semaglutide, and 53% after 52 weeks off tirzepatide. Researchers also reported that semaglutide and tirzepatide improved several obesity-related complications in selected subgroup analyses. Those signals included normoglycemia restoration or diabetes remission in glycemic subgroups, fewer heart-failure hospitalizations, and benefits in selected MASLD, obstructive sleep apnea, and knee osteoarthritis outcomes. The primary body-weight outcome was rated high certainty by GRADE, although the authors noted limited long-term follow-up, inconsistency in some outcomes, and sparse head-to-head data. Overall, the review described a broad but uneven evidence base.
Frequently Asked Questions
What's the latest on GLP-1 receptor agonists for obesity and weight management?
A Nature Medicine network meta-analysis of 56 randomized trials covering 60,307 adults compared six obesity medications. Each agent was associated with greater total body-weight loss than placebo at the study endpoint, and semaglutide and tirzepatide were the only medications surpassing 10% total body-weight loss in the pooled endpoint analysis. Direct head-to-head data were sparse, so most relative estimates came from indirect network comparisons. The primary body-weight outcome was rated high certainty by GRADE, while the authors flagged limited long-term follow-up and inconsistency in some secondary outcomes.
What's new in obesity medicine for primary care?
Beyond the weight-loss ordering, the analysis differentiated agents on cardiometabolic and durability signals relevant to primary care prescribing. Tirzepatide showed the largest HbA1c reduction, while liraglutide and semaglutide had larger fasting plasma glucose declines. Semaglutide was the only agent associated with a significantly lower rate of major adverse cardiovascular events overall; tirzepatide was linked to fewer heart-failure hospitalizations; and semaglutide and naltrexone plus bupropion were associated with lower cardiovascular mortality. Naltrexone plus bupropion also increased systolic blood pressure, whereas several other medications improved blood pressure and lipid measures. Post-discontinuation weight regain was 47% after liraglutide, 43% at 26 weeks and 67% at 52 weeks after semaglutide, and 53% at 52 weeks after tirzepatide.
Where can I find CME on obesity and dietary management?
ReachMD's Advances in Obesity Management Learning Center hosts free, accredited CME on pharmacotherapy selection, lifestyle and dietary co-management, and longitudinal care of adults with obesity. The Endocrinology CME hub aggregates additional accredited education across GLP-1 receptor agonists, dual incretins, and obesity-related complications. Both are free after a no-cost ReachMD registration: Advances in Obesity Management and Endocrinology CME.
What were the safety findings across obesity medications in this network meta-analysis?
Investigators found no significant overall between-group difference in treatment discontinuation across the reviewed trials. Serious adverse events were generally not increased, although naltrexone plus bupropion was an exception. Naltrexone plus bupropion also increased systolic blood pressure, while several other medications improved blood pressure and lipid measures. The analysis did not include head-to-head comparisons of agent-specific gastrointestinal or neuropsychiatric tolerability at the level of individual labelled adverse events — most relative estimates came from indirect network comparisons.
How should clinicians interpret these comparative findings — and where are they limited?
The review described a broad but uneven evidence base. The primary body-weight outcome was rated high certainty by GRADE; however, the authors noted limited long-term follow-up, inconsistency in some outcomes, and sparse head-to-head data, meaning most cross-drug comparisons rested on indirect network estimates rather than direct comparisons. At 52 weeks, orlistat was the only included agent without a significant advantage over placebo. Cardiovascular and metabolic signals varied by medication rather than by drug class. Subgroup signals — including normoglycemia restoration or diabetes remission in glycemic subgroups, fewer heart-failure hospitalizations, and benefits in selected MASLD, obstructive sleep apnea, and knee osteoarthritis outcomes — were reported for semaglutide and tirzepatide but apply to selected populations within the included trials.